NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $14.09 +0.03 (+0.21%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amarin Stock (NASDAQ:AMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amarin alerts:Sign Up Key Stats Today's Range$14.02▼$14.2350-Day Range$13.55▼$16.4752-Week Range$12.96▼$20.90Volume36,563 shsAverage Volume51,486 shsMarket Capitalization$297.58 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingSell Company Overview Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies. The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. Since its initial U.S. approval in 2012, Vascepa has received marketing authorizations in key markets including Canada, the European Union and Japan, often through strategic partnerships with regional pharmaceutical companies. Amarin manages its own commercial organization in the United States and leverages licensing agreements to support distribution and patient access abroad. In addition to its marketed portfolio, Amarin is conducting ongoing research to explore new indications for Vascepa and to expand its understanding of lipid-modifying therapies. Its clinical programs aim to investigate potential benefits in a range of cardiovascular and metabolic conditions. The company operates with a leadership team comprised of seasoned professionals in biopharmaceutical R&D, regulatory affairs and commercial strategy, supported by research facilities in the United States and Europe.AI Generated. May Contain Errors. Read More Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 16% of companies evaluated by MarketBeat, and ranked 840th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingSell Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.Downside RiskAmarin has a consensus price target of $13.00, representing about 7.7% downside from its current price of $14.09.Amount of Analyst CoverageAmarin has only been the subject of 3 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amarin are expected to grow in the coming year, from ($1.14) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.65% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 9.77.Change versus previous monthShort interest in Amarin has recently increased by 3.68%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.35 News SentimentAmarin has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amarin this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by Insiders4.21% of the stock of Amarin is held by insiders.Percentage Held by Institutions22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRN Stock News HeadlinesJPMorgan Chase & Co. Initiates Coverage on Amarin (NASDAQ:AMRN)August 23 at 1:43 AM | americanbankingnews.comAmarin (AMRN) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | fool.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 23 at 1:00 AM | Base Camp Trading (Ad)Amarin Earnings Call: Cost Cuts, Cash Strength, Mixed SalesAugust 3, 2026 | theglobeandmail.comAmarin expects positive full-year 2026 cash flow as VASCEPA market share reaches 48% and Europe demand rises 69%July 30, 2026 | seekingalpha.comAmarin Corporation plc (AMRN) Q2 2026 Earnings Call TranscriptJuly 29, 2026 | seekingalpha.comAmarin's Q2 Earnings Beat Estimates, Revenues Fall ShortJuly 29, 2026 | finance.yahoo.comAmarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue ChallengesJuly 29, 2026 | finance.yahoo.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $13.95 at the start of the year. Since then, AMRN shares have increased by 1.0% and is now trading at $14.09. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) announced its quarterly earnings data on Wednesday, February, 25th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.28. The biopharmaceutical company had revenue of $49.22 million for the quarter, compared to the consensus estimate of $50.62 million. Amarin had a negative trailing twelve-month return on equity of 0.20% and a negative net margin of 14.56%. Read the conference call transcript. When did Amarin's stock split? Amarin shares reverse split before market open on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. Who are Amarin's major shareholders? Amarin's top institutional shareholders include GAMMA Investing LLC (0.01%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings2/25/2026Today8/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 AMRN's financial health is in the Yellow zone, according to TradeSmith. AMRN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Price Target for Amarin$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside-7.7%Consensus RatingSell Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.80 million Net Margins-14.56% Pretax Margin-13.73% Return on Equity-0.20% Return on Assets-0.14% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio2.67 Sales & Book Value Annual Sales$213.65 million Price / Sales1.39 Cash Flow$0.36 per share Price / Cash Flow39.03 Book Value$21.00 per share Price / Book0.67Miscellaneous Outstanding Shares21,120,000Free Float20,234,000Market Cap$297.58 million OptionableOptionable Beta0.81 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AMRN) was last updated on 8/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
